Cargando…

Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease

Thrombosis is one of the most frequent complications affecting children with congenital heart disease (CHD). Palliative and reparative cardiac surgeries are some of the main players contributing to the thrombosis risk in this patient population. Additional risk factors related to the CHD itself (e.g...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelghani, Eman, Cua, Clifford L., Giver, Jean, Rodriguez, Vilmarie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555036/
https://www.ncbi.nlm.nih.gov/pubmed/34184214
http://dx.doi.org/10.1007/s40119-021-00228-4
_version_ 1784591897901137920
author Abdelghani, Eman
Cua, Clifford L.
Giver, Jean
Rodriguez, Vilmarie
author_facet Abdelghani, Eman
Cua, Clifford L.
Giver, Jean
Rodriguez, Vilmarie
author_sort Abdelghani, Eman
collection PubMed
description Thrombosis is one of the most frequent complications affecting children with congenital heart disease (CHD). Palliative and reparative cardiac surgeries are some of the main players contributing to the thrombosis risk in this patient population. Additional risk factors related to the CHD itself (e.g., cardiac dysfunction, arrhythmias, and polycythemia in cyanotic cardiac disorders) can contribute to thrombogenicity alone or combined with other factors. Thrombotic complications have been recognized as a significant cause of morbidity and mortality in this patient population. Here, we provide an overview of the pathophysiology and risk factors for thrombosis as well as the indications for and use of different anticoagulation, antiplatelet, and thrombolytic agents. In addition, we describe some of most common thrombotic complications and their management in the pediatric CHD population.
format Online
Article
Text
id pubmed-8555036
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-85550362021-11-10 Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease Abdelghani, Eman Cua, Clifford L. Giver, Jean Rodriguez, Vilmarie Cardiol Ther Review Thrombosis is one of the most frequent complications affecting children with congenital heart disease (CHD). Palliative and reparative cardiac surgeries are some of the main players contributing to the thrombosis risk in this patient population. Additional risk factors related to the CHD itself (e.g., cardiac dysfunction, arrhythmias, and polycythemia in cyanotic cardiac disorders) can contribute to thrombogenicity alone or combined with other factors. Thrombotic complications have been recognized as a significant cause of morbidity and mortality in this patient population. Here, we provide an overview of the pathophysiology and risk factors for thrombosis as well as the indications for and use of different anticoagulation, antiplatelet, and thrombolytic agents. In addition, we describe some of most common thrombotic complications and their management in the pediatric CHD population. Springer Healthcare 2021-06-29 2021-12 /pmc/articles/PMC8555036/ /pubmed/34184214 http://dx.doi.org/10.1007/s40119-021-00228-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Abdelghani, Eman
Cua, Clifford L.
Giver, Jean
Rodriguez, Vilmarie
Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease
title Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease
title_full Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease
title_fullStr Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease
title_full_unstemmed Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease
title_short Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease
title_sort thrombosis prevention and anticoagulation management in the pediatric patient with congenital heart disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555036/
https://www.ncbi.nlm.nih.gov/pubmed/34184214
http://dx.doi.org/10.1007/s40119-021-00228-4
work_keys_str_mv AT abdelghanieman thrombosispreventionandanticoagulationmanagementinthepediatricpatientwithcongenitalheartdisease
AT cuacliffordl thrombosispreventionandanticoagulationmanagementinthepediatricpatientwithcongenitalheartdisease
AT giverjean thrombosispreventionandanticoagulationmanagementinthepediatricpatientwithcongenitalheartdisease
AT rodriguezvilmarie thrombosispreventionandanticoagulationmanagementinthepediatricpatientwithcongenitalheartdisease